Formation Bio, a pioneering startup in AI-driven drug development backed by OpenAI CEO Sam Altman, has raised $372 million in a Series D funding round led by Andreessen Horowitz, bringing its total funding to over $600 million. The company aims to streamline clinical trials and drug development processes, leveraging AI to enhance efficiency in areas such as study startup, participant recruitment, and data management. The funding will be primarily allocated to partnership acquisition and R&D. Formation Bio, formerly known as TrialSpark, was co-founded in 2016 by Benjamine Liu and Linhao Zhang, combining expertise in computational biology and software development. The company has three drug candidates in its pipeline, with the most advanced targeting chronic hand eczema, currently in phase 3 trials. Their recent collaboration with OpenAI and Sanofi aims to develop customized AI solutions for drug development, although it raises potential conflict-of-interest concerns due to Altman’s involvement. The AI in drug discovery market is expected to reach $4.9 billion by 2028, with several other startups also making significant strides in the field.
Formation Bio Secures $372M to Revolutionize Drug Development with AI
Formation Bio raises $372M to innovate drug development using AI technology.
1–2 minutes
TOP STORIES
Quantum computing is transforming industries, but it poses significant cybersecurity risks …
A coalition of state attorneys general has opened an investigation into OpenAI …
The U.S. government’s export control directive has forced Anthropic to disable its new AI models, raising questions about regulation and …
SpaceX’s recent deal with Google highlights its shift from aerospace to AI infrastructure …
Google is suing to dismantle the infrastructure behind an alleged massive AI-powered cybercrime operation …
AI usage continues to grow rapidly, even as public sentiment remains skeptical …
